The 11C-labelling of the taxane derivative BAY 59-8862 (1), a potent anticancer drug, was carried out as a module-assisted automated multi-step synthesis procedure. The radiotracer [11C]1 was synthesized by reacting [1-11C]acetyl chloride (6) with the lithium salt of the secondary hydroxy group of precursor 3 followed by deprotection. After HPLC purification of the final product [11C]1, its solid-phase extraction, formulation and sterile filtration, the decay-corrected radiochemical yield of [11C]1 was in the range between 12 and 23% (related to [11C]CO2; n=10). The total synthesis time was about 54 min after EOB. The radiochemical purity of [11C]1 was greater than 96% and the chemical purity exceeded 80%. The specific radioactivity was 16.8±4.7 GBq/µmol (n=10) at EOS starting from 80 GBq of [11C]CO2. Copyright © 2006 John Wiley & Sons, Ltd.
抗肿瘤药物taxane衍
生物BAY 59-8862(1)的11C标记是采用模块辅助自动化多步合成法进行的。放射性示踪剂[11C]1由[1-11C]
乙酰氯(6)与先导物3的次级羟基
锂盐反应,然后进行脱保护来合成。对最终产物[11C]1进行HPLC纯化、固相萃取、配制和无菌过滤之后,[11C]1的衰变校正放射
化学产率在12%至23%之间(以[11C]CO2计,n=10)。
EOB之后总的合成时间约54分钟。[11C]1的放射
化学纯度大于96%,
化学纯度超过80%。EOS时,以[11C]CO2计,起始比活度为80 GBq,[11C]1的比活度为16.8±4.7 GBq/µmol(n=10)。版权所有 © 2006 John Wiley & Sons, Ltd.